Leading a Culture of Innovation
Practices
Diligence is the Hallmark of Our Services
Recent News
Read written Recent News About IP and Technology
Financial Post
2025
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options Patients treated with elafibranor versus placebo showed sign…...
Read MoreGlobeNewswire
2025
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
PARIS, FRANCE, 24 April 2025 Ipsen (Euronext: IPN; ADR: IPSEY) will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver (EASL) congress as an or…...
Read MoreGlobeNewswire
2025
STMicroelectronics Reports 2025 First Quarter Financial Results
PR No: C3332C STMicroelectronics Reports 2025 First Quarter Financial Results Q1 net revenues $2.52 billion; gross margin 33.4%; operating income......
Read MoreColumbia.edu
2025
How Firm Governance Could Address the Economic Downside of Non-Competes in the Tech Sector
Issues of labor mobility gained significant attention last year following U.S. bans on non-compete agreements. While the debate on non-competes has many dimensions, this post focuses on how to address firm governance, improve labor welfare, and reduce the los…...
Read MoreInternational Business Times
2025
Don't Let Big Business Stack The Deck Against Small Inventors
Big business lobbyists are winning an obscure -- but hugely consequential -- battle over the future of the judicial system. If these lobbyists continue to get their way, small businesses and their workers will be the biggest losers....
Read More
GlobeNewswire
2025
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced plans to pres…...
Read MoreOur Insights
Insight, Story & Blog
Global Patent Wars: Lessons from High-Profile Case Studies
Read More
The Art and Science of Depositions in Federal Civil Litigation: A Comprehensive Guide
Read More
The Art of Defending Depositions in Federal Court: A Comprehensive Guide
Read More
Understanding Patent and Trade Dress Marking Requirements: A Comprehensive Guide for Businesses and Practitioners
Read More
Preparing Your Startup for Capital Raising: A Comprehensive Guide
Read MoreGet in Touch
Ready to work
together? Let's go!
MC Law loves hearing from you. Send us a message to inquire how we can solve your legal issues.
Phone: +1 202.409.1003
Email: contact@mclaw.io
Professionals
OFFICES
PROFESSIONALS
OFFICES
